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BACKGROUND: Epidermal growth factor receptor (EGFR), evaluated by immunohistochemistry, has been shown to have prognostic
significance in patients with colorectal cancer. Gene copy number (GCN) of EGFR and KRAS status predict response and outcome in
patients treated with anti-EGFR therapy, but their prognostic significance in colorectal cancer patients is still unclear.
METHODS: We have retrospectively reviewed the baseline EGFR GCN, KRAS status and clinical outcome of 146 locally advanced
rectal cancer (LARC) patients treated with preoperative chemoradiotherapy. Pathological response evaluated by Dworak’s tumour
regression grade (TRG), disease-free survival (DFS) and overall survival (OS) were analysed.
RESULTS: Tumour regression grade 4 and TRG3–4 were achieved in 14.4 and 30.8% of the patients respectively. Twenty-nine (19.9%)
and 33 patients (19.2%) had an EGFR/nuclei ratio 42.9 and CEP7 polisomy 450% respectively; 28 patients (19.2%) had a KRAS
mutation. Neither EGFR GCN nor KRAS status was statistically correlated to TRG. 5-year DFS and OS were 63.3 and 71.5%,
respectively, and no significant relation with EGFR GCN or KRAS status was found.
CONCLUSION: Our data show that EGFR GCN and KRAS status are not prognostic factors in LARC treated with preoperative
chemoradiation.
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Epidermal growth factor receptor (EGFR) protein expression,
evaluated by immunohistochemistry (IHC), has been shown to
have prognostic significance in patients with colon cancer
(Watanabe et al, 2001). In locally advanced rectal cancer (LARC)
treated with preoperative chemoradiotherapy (CTRT), baseline
EGFR (IHC) expression predicts a poor tumour downstaging (Kim
et al, 2006) and is also an independent prognostic factor for local
recurrence (Azria et al, 2005; Giralt et al, 2005; Li et al, 2006).
Moreover, we have shown that EGFR expression on the residual
tumour after neoadjuvant CTRT is an independent prognostic
parameter for disease-free survival (DFS; Bertolini et al, 2007).
However, IHC is a semi-quantitative method that lacks a
standardised immunostaining and scoring system and is subject
to inter-observer variation (Atkins et al, 2004; Shia et al, 2005).
EGFR gene copy number (GCN) determined by FISH has been
proposed as a more reliable assay than IHC to determine
the sensitivity of anti-EGFR drugs (Chung et al, 2005; Moroni
et al, 2005; Cappuzzo et al, 2008) but the prognostic role of EGFR
GCN is unclear.
KRAS mutation status has been shown to be a predictive factor
for response to anti-EGFR monoclonal antibodies in metastatic
colorectal cancer (Bokemeyer et al, 2009; Van Cutsem et al, 2009)
and, recently, KRAS wild-type status has been recognised by the
US FDA and EMEA as a predictive factor to select patients
candidate to receive cetuximab or panitumumab. We have also
shown that EGRF GCN and KRAS mutation status correlate
with pathological response to preoperative chemoradiation and
cetuximab in LARC (Bengala et al, 2009).
To further explore the prognostic and predictive role of EGFR
GCN and KRAS mutation status, we have analysed our database of
patients with LARC treated with preoperative radiation therapy
and fluoropyrimidine-based chemotherapy. Objectives of the study
were to correlate the GCN and KRAS status with the pathological
response according to Dworak’s tumour regression grade (TRG),
DFS and overall survival (OS).
MATERIALS AND METHODS
Patients and treatment
We have retrospectively analysed data of 146 patients with
LARC who were treated with preoperative chemotherapy at our
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sinstitution between May 1998 and October 2005. The treatment
included pelvic radiotherapy (2Gy per fraction for 25 fractions) in
a large pelvic field involving the tumour mass and regional lymph
nodes, and concomitant chemotherapy with continuous infusion
5-fluorouracile (5-FU) with or without oxaliplatin or capecitabine.
5-Fluorouracil was administered at the dose of 225mgm
 2 per day
as i.v. continuous infusion 7 days a week for 5 weeks; capeci-
tabine was administered at 825mgm
 2 b.i.d. continuously for all
the duration of radiotherapy; oxaliplatin was administered at
60mgm
 2 weekly in combination with 5-FU 225mgm
 2 per day
as i.v. continuous infusion 7 days a week for 5 weeks. Surgery was
performed 6–8 weeks after the end of combined treatment. A more
detailed report of the staging procedure and treatment plan has
been already published (Gavioli et al, 2005).
Tissue samples and pathology assessment
All patients underwent tumour biopsy for diagnostic purpose
before starting the treatment. Several 3mm-thick sections were
obtained from a representative formalin-fixed and paraffin-
embedded block where the neoplastic component was at least
the 80% of the tissue. At the time of surgery, pathologic evaluation
in the resection specimens included TNM categories, stage
grouping, number of examined/involved lymph nodes and tumour
differentiation. All pathological and molecular assessments were
performed by dedicated pathologists at our University Hospital.
Tumour regression was semi-quantitatively determined by the
amount of viable tumour vs the amount of fibrosis, as described by
Dworak et al (1997) and validated by Rodel et al (2005). Tumour
regression grade 0 was defined as no regression; TRG1, minor
regression (dominant tumour with fibrosis in p25% of the tumour
mass); TRG2, moderate regression (dominant tumour with fibrosis
in 26–50% of the tumour mass); TRG3, good regression (more
than 50% tumour regression) and TRG4, total regression
(no viable tumour cells, only fibrotic mass).
EGFR FISH
Fluorescence in situ hybridisation (FISH) studies were performed
on selected sections of paraffin-embedded tissue areas, containing
representative malignant cells, using the LSI EGFR Spectrum
Orange/CEP7SpectrumGreen probe (Vysis Inc., Downer’s Grove,
IL, USA). Tissue sections of 4mm thickness were placed on
electrostatically charged slides, air dried and baked overnight at
561C. The slides were de-waxed in xylene for 2 15min, immersed
in 100% ethanol for 2 5min and in 95% ethanol for 2 5min.
Air-dried tissue sections were treated with a Paraffin Pretreatment
Kit (Vysis Inc.). The slides were briefly incubated in 0.2moll
 1
HCl for 20min, washed with Wash Buffer, incubated for 30min at
801C with Pretreatment Solution (NaSCN), washed with Wash
Buffer and finally treated in a Protease I solution (0.5mgml
 1
protease buffer; pH 2) for 10–12min at 371C.
After adding 10ml of the hybridisation probe and placing a
coverslip, denaturation and hybridisation of DNA was performed
using the metal block of a thermocycler (HyBrite; Vysis Inc.).
The denaturation was carried out at 831C for 3min and the
hybridisation was carried out overnight at 371C. After hybridisa-
tion the excess of the probes was washed in 2  SSC/0.3% NP-40 at
731C for 2min. The nuclei were counterstained with 1000ngml
 1
DAPI/Antifade (4.6-diamidine-2-phenyl indole; Vysis Inc.). For the
scoring, a Zeiss Axioscope fluorescence microscope (Carl Zeiss
Inc., Jena, Germany) was used, equipped with a specially designed
filter combination: the EGFR sequence was visualised with a
Orange filter, the chromosome 7 centromere sequence was
visualised with a Green filter and the nuclei were identified with
a DAPI filter. A triple band pass filter (Orange, Green and DAPI;
Vysis Inc.) was also used. Hybridisation signals were scored in at
least 200 intact non-overlapping nuclei and FISH analysis was
performed independently by two observers using constant
adjustment of microscope focus because signals were located at
different focal planes. Representative images of each specimen
were acquired with a high-performance CCD camera in mono-
chromatic layers that were subsequently merged by the Quips
PathVysion Software (Vysis Inc.).
Epidermal growth factor receptor gene status was scored as the
average number of EGFR red signals per nucleus and as the
ratio between EGFR red signals and CEP7 green signals. Polisomy
of EGFR gene was defined as an increase of EGFR red signals
(X three signals per nucleus) paralleled by the same increase of
chromosomes 7 (where the EGFR gene is located) as measured by
the number of CEP 7 green signals per nucleus. High GCN was
defined as EGFR/nuclei ratio X2.9 or an EGFR/CEP7 polysomy
43 in at least 50% of the cells. All cases were scored and reviewed
by two observers (SB and NB) and inter-observer disagreement
was discussed in an institutional meeting.
DNA extraction and KRAS mutation analysis
KRAS mutation status was analysed at the Laboratory of Cell
Biology of the Department of Pathology, University of Modena and
Reggio Emilia, Modena, Italy.
Three haemaxytolin-eosin-stained sections (5mm thick) from a
representative paraffin-embedded block were applied on non-
cover-slipped slides for microdissection and DNA extraction.
Briefly, microdissection was performed under direct observation
with an inverted microscope using a sterile needle. Each
microdissected sample was directly transferred to an Eppendorf
tube containing digestion buffer (2mgml
 1 proteinase K in 50mM
Tris (pH 8.5), 1mM EDTA, 0.5% Tween 20). The tubes were then
incubated overnight at 561C, and followed by 10min of incubation
at 951C to eliminate any remaining proteinase K activity. PCR
was performed in 20ml reactions containing 2.0ml DNA, 2ml
commercial PCR buffer (Applied Biosystems, Foster City, CA,
USA), 2.0mM of MgCl2, 200mM of each dNTP, 20pmol of each
primer, and 3U AmpliTaq Gold polymerase (Applied Biosystems).
PCR reaction was carried out on Uno II Thermoblock (Biometra,
Gottingen, Germany). Initial denaturation at 951C for 10min was
followed by 41 cycles, and a final extension step (10min at 721C).
The cycles included denaturation at 951C for 1min, annealing at
521C for 1min and extension at 721C for 2min. Exon 2 of KRAS
was PCR amplified using intron-based primers to investigate the
mutational status of KRAS codons 12 and 13, because it is
frequently founded mutated in colorectal cancer. The forward
and reverse oligonucleotide primers used to amplify KRAS
exon 2 were: forward, 50-CATGTTCTAATATAGTCACA-30; reverse,
50-AACAAGATTTACCTCTATTG-30.
The amplified DNA was electrophoresed on 2% agarose gel
for 1h at 110V. The amplification products were then purified by
using MinElute PCR purification Kit (Qiagen, Valencia, CA, USA)
as indicated by the manufacturer. PCR products were then
amplified in both directions with ABI Prism BigDye Terminator
version 1.1 Cycle Sequencing kit (Applied Biosystems), using the
same primers as those used for PCR. PCR products were finally
purified by Centri-Sep Spin Columns (Applied Biosystems) and
subsequently ran on the ABI Prism 310 Automatic Sequencer
(Applied Biosystems). The data were analysed with the Sequencing
Analysis 5.2 software (Applied Biosystems).
Statistical analysis
The study, including the molecular analysis, was approved by the
ethical committee of the Province of Modena.
Tumour downstaging and the pathological response, based on
Dworak’s TRG, were associated with biological characteristics with
Fisher’s exact test.
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sDisease-free survival was defined as the interval from the date of
diagnosis until the date of tumour recurrence, second primary
tumour or death with or without recurrence. Overall survival was
defined as the date of study entry until the date of death. The DFS
and OS curves were calculated according to the Kaplan–Meier
method. Long-rank test was used to compare DSF and OS
according to pathological response and tumour biomarkers.
Hazard ratios and 95% confidence intervals for recurrence or
death were calculated to evaluate the association with the
pathological response and the tumour biomarkers using the
univariate Cox proportional hazard model.
Statistical significance was set at Po0.05. All the analyses were
conducted using STATA 10.0 (College Station, TX, USA).
RESULTS
Patient characteristics are described in Table 1. Median age was 64
years (range 26–78). At diagnosis, clinical stage defined with
ultrasonography was stage II in 59 patients (IIA 48 patients, IIB 11
patients), stage III in 83 patients (IIIA 5 patients, IIIB 78 patients)
and stage IV in 4 patients. All the patients received pelvic radiation
therapy; concomitant chemotherapy was 5-FU in 98 patients
(67.1%), 5-FU in combination with oxaliplatin in 34 patients
(23.3%) and capecitabine in 14 patients (9.6%). A pathological
complete response classified as Dworak’s TRG4 was achieved in
21 patients (14.4%); a TRG3 was observed in 24 patients (16.4%),
TRG2 in 46 patients (31.5%); TRG1 in 48 patients (32.9%), TRG0 in
3 patients (2.1%). Tumour and lymph node downstaging was
observed in 85 patients (58.2%).
Biomarker expression and response
EGFR GCN was evaluated as EGFR/nuclei ratio and as CEP7
polisomy. Median EGFR/nuclei ratio was 2.3 (range 1.1–3.5).
Median CEP7 polisomy was 28.3% (range 0–78%). A high EGFR/
nuclei ratio (X2.9) and a low EGFR/nuclei ratio (o2.9) was
present in 19.9 and 78.8% patients respectively; a high CEP7
polisomy (X50%) and a low polisomy (o50%) was observed in
22.6 and 75.3% patients respectively. Among the 113 assessable
patients with low EGFR/nuclei ratio, 15 (13.3%) and 36 (31.3%)
had a TRG4 and TRG3–4 respectively, compared with 6 (22.2%)
and 9 (33.3%) of the 27 assessable patients with high EGFR/nuclei
ratio (P¼0.19 and 0.53). Moreover, 14 (12.7%) and 36 (32.7%) of
the 110 assessable patients with low CEP7 polisomy had a TRG4
and TRG3–4 respectively, compared with 7 (23.3%) and 9 (30.0%)
of the 30 patients with high CEP7 polisomy (P¼0.13 and 0.48)
(Table 2).
The downstaging rate was 59.6 vs 65.5% in patients with low and
high EGFR/nuclei ratio respectively (P¼0.36) and 64.8 and 48.5%
in patients with low and high CEP7 polisomy respectively
(P¼0.07) (Table 2).
A wild-type KRAS was reported in 79.5% of the patients and in
these patients the rate of TRG4 was 16.7%; a mutated KRAS was
found in 19.2% of the patients with a TRG4 of 7.4%; this difference
is not significant (P¼0.18). The rate of TRG3–4 was higher in
wild-type KRAS (35.1%) in comparison to mutated status (18.5%)
and this difference approaches a statistical significance (P¼0.07)
(Table 2).
Biomarker expression and survival
At a median follow-up of 4.45 years (range 0.29–10.6), median DFS
was 8 years (range 0.27–10.6) (Figure 1). The 5- and 10-year DFS
were 63.6 and 39.8% respectively. The 5-year DFS was 77% for
the patients with TRG3–4 and 58% for the patients with TRG0–2
(HR, 0.36; 95% CI: 0.18–0.74; P¼0.005; Figure 2). The 5-year DFS
was 64.2 and 62.2% for patients with low vs high EGFR/nuclei
respectively (HR, 0.99; 95% CI: 0.51–1.94; P¼0.99); 67.2 and
51.1% for patients with low vs high CEP7 polisomy respectively
(HR, 1.43; 95% CI: 0.78–2.60; P¼0.24); 64.7 and 61.3% for
patients with wild-type vs mutated KRAS respectively (HR, 0.94;
95% CI: 0.49–1.83; P¼0.86).
Median OS was 9.0 years (range 0.26–10.6) (Figure 3). At 5 and
10 years OS rates were 71.5 and 44.9% respectively. At 5 years, OS
rates were 89.7 and 64.8% for the patients who achieved a TRG3–4
and patients with TRG 0–2 respectively (HR, 0.26; 95% CI:
0.10–0.66; P¼0.005) (Figure 4); 72.3% for both wild-type and
mutated KRAS patients; 71.0 and 76.2% for patients with low vs
high EGFR/nuclei ratio respectively (HR, 1.13; 95% CI: 0.54–2.39;
P¼0.74); 75.3 and 60.9% for the patients with low vs high CEP7
polisomy respectively (HR, 1.83; 95% CI: 0.94–3.57; P¼0.07).
Table 1 Patient characteristics
Number of patients 146
Median age, years (range) 64 (26–78)
Characteristic N %
Gender
Male 86 58.9
Female 60 48.1
PS (ECOG scale) 0 100
Clinical stage
uT2N1 5 3.4
uT3N0 48 32.9
uT3N1 63 43.2
uT4N0 11 7.5
uT4N1 15 10.3
Any TNM1 4 2.7
Chemotherapy concurrent to RT
5-FU 98 67.1
5-FU+Oxaliplatin 34 23.3
Capecitabine 14 9.6
EGFR/nuclei ratio
o2.9 115 78.8
X2.9 29 19.9
NA 2 1.4
CEP7 polisomy (43 copies)
o50% 110 75.3
X50% 33 22.6
NA 3 2.1
KRAS
Wild type 116 79.5
Mutated 28 19.2
NA 2 1.4
Pathological response (Dworak’s grade)
TRG 4 21 14.4
TRG 3 24 16.4
TRG 2 46 31.5
TRG 1 48 32.9
TRG 0 3 2.1
NA 4 2.7
Downstaging
Yes 85 58.2
Not 55 37.7
NA 6 4.1
Abbreviations: ECOG¼ eastern cooperative oncology group; EGFR¼epidermal
growth factor receptor; 5-FU¼5-fluorouracile; NA¼ not available; PS¼performance
status; TRG¼tumour regression grade.
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sDISCUSSION
Epidermal growth factor receptor expression has been shown to be
associated with disease recurrence and poor survival in colon
cancer (Iqbal and Lenz, 2001; Watanabe et al, 2001; Galizia et al,
2006). Moreover, the predictive role of EGFR expression on
tumour response and locoregional recurrence has been extensively
investigated in patients with LARC treated with preoperative
chemoradiation therapy (Giralt et al, 2002; Azria et al, 2005).
All the data show that EGFR expression, evaluated by IHC, is a
predictive factor for poor tumour response and local recurrence
after preoperative chemoradiation therapy and curative surgery
for rectal cancer. Moreover Giralt et al (2005) and Li et al (2006)
reported that baseline EGFR expression is an independent
prognostic factor for DFS and distant metastasis-free survival.
We recently analysed patients with LARC treated with preoperative
CTRT and we were unable to confirm that baseline EGFR
expression evaluated by IHC is a predictive factor for response
as well as prognostic factor on survival; on the contrary, EGFR
expression by IHC on residual tumour after preoperative
Table 2 EGFR gene copy number, KRAS status, pathological response and downstaging
EGFR/nuclei ratio CEP7 polisomy KRAS status
o2.9 X2.9 P-value o50% X50% P-value Wild type Mutated P-value
Pathological response
Assessable patients, n 113 27 110 30 114 27
TRG 4, n (%) 15 (13.3) 6 (22.2) 0.19 14 (12.7) 7 (23.3) 0.13 19 (16.7) 2 (7.4) 0.18
TRG 3–4, n (%) 36 (31.9) 9 (33.3) 0.53 36 (32.7) 9 (30.0) 0.48 40 (35.1) 51 (8.5) 0.07
Downstaging
Assessable patients, n 109 29 105 33 111 28
Downstaging, n (%) 65 (59.6) 19 (65.5) 0.36 68 (64.8) 16 (48.5) 0.07 69 (62.2) 16 (57.1) 0.39
Abbreviations: EGFR¼epidermal growth factor receptor; TRG¼tumour regression grade.
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Figure 1 Disease-free survival of entire group of patients.
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schemoradiation is an independent poor prognostic factor for
disease recurrence (Bertolini et al, 2007). Possible explanation
for these discrepancies can be unreliable techniques of immunos-
taining and scoring, heterogeneity of EGFR expression, and high
and low affinity of EGFR. Moreover polymorphism of EGFR
has been shown to predict tumour response to CTRT and loco-
regional tumour recurrence after CTRT (Zhang et al, 2005;
Spindler et al, 2006).
In this study we show that EGFR GCN is not predictive of
response to preoperative chemoradiation therapy and is not a
prognostic factor for DFS and OS. Interestingly, we had previously
reported that high EGFR GCN is predictive of TRG3–4 in patients
treated with chemoradiation in combination with cetuximab
(Bengala et al, 2009). These evidences are not in contrast because
while EGFR GCN may not have a prognostic value it can be a
possible predictive factor of response to anti-EGFR monoclonal
antibody cetuximab.
KRAS mutation status has been extensively studied as a
predictive factor of resistance to anti-EGFR monoclonal anti-
bodies. In our study, KRAS mutation status is not a predictive
factor for neither pathologic response nor downstaging, although
the rate of pathological regression grade 3–4 was 35.1 vs 18.5% in
patients with wild-type and mutated KRAS status respectively
(P¼0.07). Moreover, KRAS status did not predict DFS and OS.
Two large prospective studies conducted in stage II–III colon
cancer (Roth et al, 2010) and in advanced colorectal cancer
(Bokemeyer et al, 2009; Van Cutsem et al, 2009) have shown that
KRAS mutation is not a prognostic factor. Conversely, two large
collaborative studies, the RASCAL trials, have reported an
increased risk of recurrence and death in patients with colon
cancer and KRAS mutation (Andreyev et al, 1998, 2001). In the
study by Roth et al (2010), tumour specimens were prospectively
collected and analysed in a central laboratory, whereas in the
RASCAL trials the specimens were retrospectively analysed in local
laboratories and this could explain the contradictory results.
Moreover, the second RASCAL trial reported a poor outcome only
for a small subset of patients bearing a G12V mutation raising the
question on the possible prognostic relevance of specific KRAS
mutations (Andreyev et al, 2001). Unfortunately the study by Roth
et al did not have a sufficient statistical power to detect a possible
prognostic role of different KRAS mutations. Differences in patient
population (colorectal vs locally advanced rectal), treatments
(chemotherapy vs chemoradiation) and sample sizes might
account for the inconsistency of available data on prognostic role
of KRAS mutation across these studies.
In conclusion, our data show that EGFR GCN and KRAS
mutation status are neither predictive nor prognostic factors for
pathological tumour response and DFS in LARC patients treated
with preoperative chemoradiation. On the basis of these data,
KRAS status should not be used to select therapies other than anti
EGFR antibodies.
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